C3 and Fabry disease: Targeting the C3a–C3aR and C5a–C5aR1 pathways and their influence on adhesion molecule-mediated immune cell infiltration holds significant promise for mitigating inflammation and potentially halting or slowing the progression of organ damage in Fabry disease.